Conservative treatment of atypical hyperplasia and endometrial carcinoma: immunohistochemical aspects

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective: To test the algorithms of conservative hormonal therapy using buserelin depot and levonorgestrel releasing intrauterine system in women with identified atypical endometrial hyperplasia and/or adenocarcinoma of the uterine body and unrealized fertility.

Materials and methods: The results of the treatment with hormonal drugs were retrospectively evaluated in 52 reproductive-aged patients diagnosed with atypical endometrial hyperplasia ICD-O code 8380/2 (n=40, 77.1%) and well-differentiated (grade 1) endometrioid adenocarcinoma of the uterine body ICD-O code 8380/3 (n=12, 22.9%). The expression of immunohistochemical markers, namely ER, PR, Ki-67, Bcl-2, and E-cadherin, was studied in endometrial samples before and after the treatment.

Results: A complete response to the treatment was noted in 100% of cases. The spontaneous pregnancy occurred in 22 cases (40.4%). The recurrence of the disease was not detected in the patients participating in the study for 15 years, the five-year survival rate was 100%. The study of immunohistochemical markers revealed differences in their expression in endometrial samples of the patients with atypical endometrial hyperplasia and endometrioid adenocarcinoma of the uterine body.

Conclusion: The complex use of gonadotropin-releasing hormone agonists (buserelin depot) with the subsequent insertion of levonorgestrel releasing intrauterine device is an effective method of treating atypical endometrial hyperplasia and stage IA well-differentiated endometrioid adenocarcinoma without invasion into the myometrium in reproductive-aged women with unrealized fertility.

Full Text

Restricted Access

About the authors

Alexander I. Pashov

Immanuel Kant Baltic Federal University

Author for correspondence.
Email: pachov@mail.ru
ORCID iD: 0000-0001-5346-9185

Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology of the Medical Institute

Russian Federation, Kaliningrad

Evgenia N. Sivova

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Email: janesivova@gmail.com

PhD, Assistant at the Department of Obstetrics and Gynecology

Russian Federation, Krasnoyarsk

Larisa V. Volkova

Immanuel Kant Baltic Federal University

Email: volkovalr16@gmail.com
ORCID iD: 0000-0003-0938-8577

Dr. Med. Sci., Head of the Laboratory of Immunohistochemical, Pathological Anatomical and Clinical Diagnostics, Professor at the Department of Obstetrics and Gynecology of the Medical Institute

Russian Federation, Kaliningrad

Valeriya V. Rachkovskaya

Immanuel Kant Baltic Federal University

Email: Losevavaleria2104@mail.ru
ORCID iD: 0000-0002-4221-693X

Post-graduate student of the Department of Obstetrics and Gynecology of the Medical Institute

Russian Federation, Kaliningrad

References

  1. Kaprin A.D., Starinsky V.V., Shakhzadova A.O., eds. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Moscow: P.A. Herzen MNROI − branch of the NMRC of Radiology, Ministry of Health of Russia; 2020. 252p. (in Russian).
  2. Orazov M.R., Khamoshina M.B., Mullina I.A., Artemenko Yu.S. Endometrial hyperplasia – from pathogenesis to effective therapy. Obstetrics and Gynecology: News, Opinions, Training. 2021; 9(3): 21-8. (in Russian). https://dx.doi.org/10.33029/2303-9698-2021-9-3-21-28.
  3. Hutt S., Tailor A., Ellis P., Michael A., Butler-Manuel S., Chatterjee J. The role of biomarkers in endometrial cancer and hyperplasia: a review of the literature. Acta Oncol. 2019; 58(3): 342-52. https://dx.doi.org/10.1080/ 0284186X.2018.1540886.
  4. Bokhman Ya.V. Guide to oncogynecology. St Petersburg: Foliant; 2002. 542p. (in Russian).
  5. Novikova O.V., Novikova E.G., Lozovaya Yu.A., Chulkova O.V., Pronin S.M. Self-hormone therapy as an alternative to surgical treatment of precancer and initial endometrial cancer in patients of reproductive age. Oncogynecology. 2015; (3): 25-33. (in Russian). https://dx.doi.org/10.18565/ aig.2019.1.104-108.
  6. Pashov A.I., Sivova E.N., Metrinsky Ya.Yu. Combined use of gonadotropin-releasing hormone agonists and intrauterine levonorgestrel-releasing system in the treatment of atypical endometrial hyperplasia in women of reproductive age. Doctor.Ru. 2020; 19(1): 58-61. (in Russian). https://dx.doi.org/10.31550/1727-2378-2020-19-1-51-54.
  7. Westin S.N., Fellman B., Sun C.C., Broaddus R.R., Woodall M.L., Pal N. et al. Prospective study of phase II of the intrauterine device levonorgestrel: a non-surgical approach to complex atypical hyperplasia and early-stage endometrial cancer. Am. J. Obstet. Gynecol. 2021; 224(2): 191.e1-191.e15. https://dx.doi.org/10.1016/j.ajog.2020.08.032.
  8. Pashov A.I., Tshay V.B., Ionouchene S.V. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study. Gynecol. Endocrinol. 2012; 28(7): 559-61. https://dx.doi.org/10.3109/09513590.2011.649813.
  9. Pronin S.M., Novikova O.V., Novikova E.G., Andreeva J.Y. Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential. Int. J. Gynecol. Cancer. 2015; 25(6): 1010-4. https://dx.doi.org/10.1097/IGC.0000000000000467.
  10. Patent No. 2428201 Russian Federation, MPK7A61K38/22, A61K38/21, A61R35/00. A method for the treatment of early endometrial cancer. Pashov A.I., Sivova E.N., Tskhai V.B. No. 2010131735/15; publ. 09/10/2011. Bull. No. 25. (in Russian).
  11. Chatzipantelis P., Koukourakis M., Balaska K., Giatromanolaki A. Endometrial stromal expression of ER, PR and B-catenin to differentiate diagnoses of hyperplasia. Int. J. Surg. Pathol. 2022; 30(5): 492-8. https://dx.doi.org/ 10.1177/10668969211065110.
  12. Samani S.M., Bojnordi T.E., Zarghampour M., Merat S., Fouladi D.F. Expression of p53, Bcl-2 and Bax in endometrial carcinoma, endometrial hyperplasia and normal endometrium: histopathological examination. J. Obstet. Gynaecol. 2018; 38(7): 999-1004. https://dx.doi.org/10.1080/01443615.2018.1437717.
  13. Travaglino A., Inzani F., Santoro A., Archuolo D., Piermattey A., Paschini S. et al. Metaplastic/reactive changes in the endometrium coexist with endometrial hyperplasia and carcinoma: morphological and immunohistochemical study. Diagnostics (Basel). 2021; 12(1): 63. https://dx.doi.org/10.3390/diagnostics12010063.
  14. WHO Classification of Tumours Female Genital Tumours. 5th ed. vol. 4: Herrington, C.S., ed. WHO classification of tumours editorial board. WHO: IARC; 2020.
  15. Nordic immunohistochemical Quality Control (NordiQC). Available at: https://nordiqc.org/index.php
  16. Danilov N.V., Andreeva Y.Y., Zavalishina L.E., Kakeeva T.V., Shikeeva A.A., Malkov P.G., Frank G.A. Tumors of the bodt and cervics unerine. Morphological diagnostics and genetics. Guide. Moscow: Practical Medicine; 2015. 304. (in Russian).
  17. Felix A.S., Weissfeld J.L., Stone R.A., Bowser R., Chivukula M., Edwards R.P., Linkov F. Factors associated with type I and type II endometrial cancer. Cancer Causes Control. 2010; 21(11):1851-6. https://dx.doi.org/10.1007/ s10552-010-96122-8.
  18. Zidan A.A., Hassan A.A., Seadah Sh.Sh.A., Ibrahim E.H., Attiah S.M. Selected immunohistochemical prognostic factors in endometrial hyperplasia versus carcinoma. J. Am. Sci. 2015; 11(4): 14-22. https://dx.doi.org/10.7860/JCDR/2017/28750.10475.
  19. Ahmed A.R.H., Muhammad E.M.S. E cadherin and CD10 expression in atypical hyperplastic and malignant endometrial lesions. J. Egypt. Natl. Canc. Instit. 2014; 26(4): 211-7. https://dx.doi.org/10.1016/j.jnci.2014.08.002.
  20. Carico E., Atlante M., Giarhieri E., Raffa S. E-cadherin and alpha-catenin expression in normal, hyperplastic and neoplastic endometrium. Anticancer Res. 2010; 30(12): 4993-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies